An upcoming funding opportunity will help researchers who have developed cutting-edge medical technologies or pharmaceuticals bring these discoveries to market.
The University of Minnesota’s MN-REACH program, a National Institutes of Health’s Research Evaluation and Commercialization Hub, is accepting pre-proposals for its third funding cycle to help commercialize new med-tech and pharma inventions. MN-REACH aims to improve health care by fostering the development of breakthrough lab innovations — such as therapeutics, preventatives, diagnostics, devices and tools — into products that create health, economic and societal benefits.
Researchers can submit pre-proposals for MN-REACH Cycle 3 funding from Monday, Jan. 25 through Thursday, Feb. 11. The following informational sessions will review eligibility for the program and the application process:
- U of M Duluth: Jan. 27, 11 a.m. to noon, 160 Life Sciences Building
- East Bank: Jan. 28, mid-morning (to be determined), Moos Tower
- St. Paul: Jan. 29, 1-2 p.m., 125 Coffey Hall
See the list of projects selected for MN-REACH funding during Cycle 1. Awardees of Cycle 2 grants will be announced in February.
In addition to providing funding opportunities to commercialize innovations, MN-REACH also provides educational opportunities for innovators that are developing their products and forming new partnerships both within and beyond the University.
Registration is now open for the free Medical Technology Commercialization Bootcamp. University faculty, staff and student health care researchers are invited to attend to learn about the commercialization process and the resources available to support bringing an innovation to market. The seminar will be held from 9 a.m. to 4 p.m. on Wednesday, Feb. 3 at the Mayo Building.
Contact email@example.com with questions.